Eczema Treatment
Eczema, also known as Atopic Dermatitis, is a very common, very itchy skin disease, usually appearing early in childhood, but some people may not develop it until adulthood.
Narrowband Ultraviolet B (NB-UVB) phototherapy is one of the standard treatments for eczema (atopic dermatitis). Clinically, it effectively suppresses inflammation of the patient's skin, improves itching, and has a high safety profile. It is suitable for infants/adolescents/pregnant women/people of all ages to use under the assessment and supervision of a doctor.
In the context of treating eczema, NB-UVB phototherapy uses a specific wavelength of ultraviolet light that has been shown to be effective in reducing skin inflammation. The therapy is generally safe and well-tolerated, making it a useful treatment option for a wide range of patients, including infants, adolescents, pregnant women, and adults. However, the treatment should always be administered under the supervision of a healthcare professional, and individual response to treatment can vary. Therefore, it's important to regularly monitor treatment progress and adjust the treatment plan as necessary.
According to the 2022 European large-scale medical literature guidelines (EuroGuiDerm), a comprehensive clinical recommendation by 29 medical experts and patient representatives from 12 European countries specifically provides guidelines for eczema, including: basic information, treatment options for different patients and detailed analysis, such as: traditional conventional immunosuppressant drugs, phototherapy, biologics, oral targeted small molecule drugs JAK inhibitors... etc. The guidelines also include: how to avoid the risk of triggering eczema, dietary interventions, education, psychology, occupation, infants, adolescents, pregnancy and lactation and other precautions... etc.
Narrowband Ultraviolet B (NB-UVB) phototherapy is recognized by EuroGuiDerm as one of the first-line treatment options for eczema. It has a significant clinical effect in relieving itching, high safety, low side effects, and for many patients who are ineffective after applying topical medications, or do not want to take/apply medication, NB-UVB phototherapy is a safe and effective option.
Reference:
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H., Calzavara Pinton, P., Christen-Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink-Wagner, A., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C., Nast, A., Nygaard, U., Redding, M., Rehbinder, E., Ring, J., Rossi, M., Serra-Baldrich, E., Simon, D., Szalai, Z., Szepietowski, J., Torrelo, A., Werfel, T. and Flohr, C. (2022), European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol, 36: 1409-1431. https://doi.org/10.1111/jdv.18345
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H., Calzavara Pinton, P., Christen-Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink-Wagner, A., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C., Nast, A., Nygaard, U., Redding, M., Rehbinder, E., Ring, J., Rossi, M., Serra-Baldrich, E., Simon, D., Szalai, Z., Szepietowski, J., Torrelo, A., Werfel, T. and Flohr, C. (2022), European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol, 36: 1904-1926. https://doi.org/10.1111/jdv.18429
